Medical Therapy. Efficacy or Lack of Efficacy

Trametinib restores the central conducting lymphatic flow in a premature infant with Noonan syndrome

Erika K. S. M. Leenders, Lotte E. R. Kleimeier, Lauren C. Weeke, Catelijne H. Coppens, Willemijn M. Klein, Jos M.T. DraaismaRadboud University Medical Center. Amalia Children’s Hospital.Netherlands Clinical Case ReportsClin Case Rep 2024; 12: DOI: 10.1002/ccr3.9164 AbstractWe describe a premature hydropic infant with Noonan syndrome and a therapy refractory chylothorax. This was shown to be due to a central conducting lymphatic anomaly.

Trametinib restores the central conducting lymphatic flow in a premature infant with Noonan syndrome Read More »

[Protective effects of 2-methoxyestradiol against hypoxic pulmonary hypertension in neonatal rats]

Ou Xie, Shan-Shan Li, Yang Luo, Le WangFirst Affiliated Hospital of Xinjiang Medical University.China Chinese Journal of Contemporary PediatricsZhongguo Dang Dai Er Ke Za Zhi 2024; 26: 757-764DOI: 10.7499/j.issn.1008-8830.2401078 AbstractObjectives: To investigate the protective effects of 2-methoxyestradiol (2ME) against hypoxic pulmonary hypertension (HPH) in neonatal rats.Methods: Ninety-six Wistar neonatal rats were randomly divided into a normoxia group, a

[Protective effects of 2-methoxyestradiol against hypoxic pulmonary hypertension in neonatal rats] Read More »

Pharmacological Gq inhibition induces strong pulmonary vasorelaxation and reverses pulmonary hypertension

Alexander Seidinger, Richard Roberts, Yan Bai, Marion Müller, Eva Pfeil, Michaela Matthey, Sarah Rieck, Judith Alenfelder, Gabriele M. KUonig, Alexander Pfeifer, Evi Kostenis, Anna Klinke, Bernd K. Fleischmann, Daniela WenzelUniversity Hospital of the Ruhr University of Bochum and Ruhr University of Bochum. University Hospital of Nottingham. Massachusetts General Hospital and Harvard Medical School. University of

Pharmacological Gq inhibition induces strong pulmonary vasorelaxation and reverses pulmonary hypertension Read More »

High-intensity Focused Ultrasound-A New Choice to Conduct Pulmonary Artery Denervation

Yonghui Xie, Taoyue Yao, Xiaogang Zhu, Fan Yang, Haoqin Fan, Shirui Cao, Huaiyang Chen, Manzhen Liao, Yuanxi Xia, Jinqiao Liu, Zhenghui Xiao, Zhou Yang, Yunbin XiaoUniversity of South China. Affiliated Children’s Hospital of Xiangya School of Medicine. Third Xiangya Hospital. Second Xiangya Hospital. Central South University. Changsha Yali High School. China Journal of Cardiovascular Translational

High-intensity Focused Ultrasound-A New Choice to Conduct Pulmonary Artery Denervation Read More »

Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns

Felipe Santelices, Daniela Masoli, Javier Katten, Alberto Toso, Matias LucoPontificia Universidad Católica de Chile. Chile Journal of PerinatologyJ Perinatol 2024; DOI: 10.1038/s41372-024-02015-0 AbstractObjective: The use of vasopressin as an adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension has increased. The objective of our study is to describe its effects on term infants.Study design: Retrospective observational study.

Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns Read More »

Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension

Satoshi Akagi, Shingo Kasahara, Teiji Akagi, Kentaro Ejiri, Toshiharu Mitsuhashi, Koji Nakagawa, Kazufumi Nakamura, Hiroshi ItoOkayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences. Johns Hopkins Bloomberg School of Public Health. Okayama University Hospital.Japan and United States Journal of the American College of Cardiology AdvancesJACC Adv 2024; 3:DOI: 10.1016/j.jacadv.2024.100887 AbstractBackground: A treatment strategy for congenital heart defects

Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension Read More »

Navigating Diagnostic and Treatment Challenges of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia

Nidhy P. Varghese, Gabriel Altit, Megan M. Gubichuk, Roopa SiddaiahBaylor College of Medicine and Texas Children’s Hospital. Montreal Children’s Hospital and McGill University. Children’s Mercy Hospital. Penn State Health Children’s Hospital.United States and Canada Journal of Clinical MedicineJ Clin Med 2024; 13: DOI: 10.3390/jcm13123417 AbstractAdvances in perinatal intensive care have significantly enhanced the survival rates of

Navigating Diagnostic and Treatment Challenges of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia Read More »

Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants

Amit V. Krishnan, Victoria Freniere, Rakesh Sahni, Diana P. Vargas Chaves, Sankaran S. Krishnan, Dimitrios Savva, Usha S. KrishnanColumbia University Irving Medical Center and New York-Presbyterian Hospital. New York Medical College.United States ChildrenChildren 2024; DOI: 10.3390/children11060703 AbstractThis is a single-center retrospective study to assess the safety and tolerability of continuous inhaled iloprost use as rescue therapy

Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants Read More »

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition

Xinyu Lia, Hui Li, Bo Feng, Xiaoyan Chen, Ting Chen, Jiafei Lu, Huating Xie, Nana Su, Houlin Chen, Chenghao Lou, Runxin Zhuang, Xi Chen, Shengwei Jin, Yu HaoSecond Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University. Ruijin Hospital and Shanghai Jiao Tong University School of Medicine. China Biomedicine and PharmacotherapyBiomed Pharmacother 2024; DOI: 10.1016/j.biopha.2024.117023

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition Read More »

Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension

Brian S. Hernandez, Rod M. Shinozaki, R. Mark Grady, Andrea Drussa, Erica Jamro-Comer, Jinli Wang, Manish AggarwalWashington University School of Medicine. Loma Linda University Children’s Hospital. United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114116 AbstractObjective: To assess the effect of treating pulmonary hypertension (PH) in infants less than 1 year of age with systemic glucocorticoids while

Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension Read More »

Scroll to Top